Bell Palsy Clinical Trial
— FACEOfficial title:
The Facial Nerve Palsy And Cortisone Evaluation (FACE) Study in Children: A Randomized Double-blind, Placebo-controlled, Multicenter Trial
Acute facial nerve palsy occur in 10-20/100 000 children/year in Sweden. About 20 % of these children will have persistent symptoms with excessive tear secretion, drooling and social problems due to asymmetry in the face. Studies on cortisone treatment to adult patients with acute facial nerve palsy have shown beneficial effects, but no studies with strong quality have been performed in children. Investigators will perform a double-blind randomized placebo-controlled multicenter trial on children with acute facial nerve palsy. Participants will be recruited consecutively at 9-12 study centers in Sweden during 2019-2020. Oral cortisone (prednisolone) 1 mg/kg x 1 in 10 days (or placebo) will be started on admission. Clinical data, including recovery will be followed-up until 12 months. The primary outcome is defined as total recovery of the facial nerve palsy, measured with the House-Brackmann scale (grade 1) at 12-months follow-up. The overall purpose is to assess the utility of cortisone treatment given to children with acute facial nerve palsy in this study. If the total recovery rate is significantly improved in the prednisolone group as compared to the placebo group, prednisolone treatment will be introduced in clinical practice for children with acute facial nerve palsy in order to reduce the risk of persistent symptoms.
Status | Recruiting |
Enrollment | 500 |
Est. completion date | December 31, 2026 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Year to 17 Years |
Eligibility | Inclusion Criteria: 1. 1-17 years of age 2. Acute peripheral unilateral facial nerve palsy 3. Less than 72 hours since debut of symptoms 4. Signed informed consent Exclusion Criteria: 1. Head trauma <1 month 2. Central or bilateral facial nerve palsy 3. Malformations in head and neck 4. Conditions not compatible with cortisone treatment (arterial hypertension, diabetes mellitus, psychiatric disorder, active or latent tuberculosis, intolerance of lactose) 5. Current or past oncological diagnosis 6. Other serious medical conditions (meningitis, encephalitis, stroke) 7. Acute otitis media 8. Signs of herpes simplex or varicella zoster infection (vesicles in the ear region) 9. Pregnancy or breastfeeding 10. Use of any systemic or inhaled steroids within 2 weeks prior onset of symptoms 11. Immunization with live vaccine 1 month prior onset of symptoms 12. Requirement of live vaccine within 2 months from start of experimental treatment (prednisolone or placebo) 13. Evaluation of primary endpoint at 12 months not feasible for any reason 14. Previously included into the FACE study |
Country | Name | City | State |
---|---|---|---|
Sweden | Barn- och ungdomsmedicin | Falun | Dalarna |
Sweden | Barnmedicin Drottning Silvias Barn- och Ungdomssjukhus Östra Sjukhuset | Göteborg | |
Sweden | Barn- och ungdomsmedicinska kliniken | Jönköping | |
Sweden | Barn och ungdomskliniken, Länssjukhuset | Kalmar | Region Kalmar |
Sweden | Barn- och ungdomsmottagning | Karlskrona | |
Sweden | HKH Kronprinsessan Viktorias Barn- och ungdomssjukhus | Linköping | |
Sweden | Akutmottagning för barn, Skåne Universitets sjukhus | Lund | |
Sweden | Barnakuten i Malmö, Skåne Universitets sjukhus | Malmö | |
Sweden | Barn- och ungdomskliniken, Vrinnevi sjukhuset | Norrköping | |
Sweden | Barn- och ungdomskliniken, Universitets sjukhuset Örebro | Örebro | |
Sweden | Barnkliniken, Skaraborgs sjukhus | Skövde | Västra Götalands Region |
Sweden | Astrid Lindgrens barnsjukhus, Karolinska Solna | Solna | |
Sweden | Astrid Lindgrens barnsjukhus, Karolinska Huddinge | Stockholm | |
Sweden | Sachsska barnsjukhuset | Stockholm | |
Sweden | Akademisk Barnsjukhuset | Uppsala |
Lead Sponsor | Collaborator |
---|---|
Dalarna County Council, Sweden | Karolinska Institutet |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Adverse events | Number of Adverse Events possibly or probably related to the study drug. | Up to 12 month (+/- 2 weeks) after inclusion | |
Primary | House-Brackmann scale | Total recovery in the two treatment groups measured with the House-Brackmann scale.
The House-Brackmann scale (I is normal function and VI is total loss of function) is chosen as primary outcome measure since it is an objective instrument, easy to perform and the one most frequently used in previous studies. The time point 12 months for evaluation of total recovery is chosen as no further improvement of the facial nerve function is expected after 12 months. |
At 12 months (+/- 2 weeks) after inclusion | |
Secondary | Sunnybrook facial grading system | Total recovery in the two treatment groups measured with the Sunnybrook scale.
The Sunnybrook scale (100 is normal function and 0 is total loss of function) is another objective scale for grading the facial nerve function. It will be used as secondary outcome measure. It is easy to perform and has been used in previous studies in children. It correlates well to the House-Brackmann scale. |
At 12 months (+/- 2 weeks) after inclusion | |
Secondary | Facial Disability Index (FDI) | Disease-specific Quality-of-Life assessment scale, with 5 functional domains (5 means no probelms and 2 or 1 means problems all the time) and 5 social domains (6 means problems all the time and 1 means no problems at all) | At 12 months (+/- 2 weeks) after inclusion | |
Secondary | Facial Clinimetric Evaluation (FaCE) Scale | Disease-specific Quality-of-Life assessment scale, with 15 functional and social domains (1 means problems all the time and 5 means no problems at all). | At 12 months (+/- 2 weeks) after inclusion | |
Secondary | Synkinesis Assessment Questionnaire (SAQ) | Subjective grading of synkinesis symptoms with 9 functional domains (1 means no problems at all and 5 means problems all the time). | At 12 month (+/- 2 weeks) after inclusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05679752 -
Effects of Massage Therapy and Facial PNF in Early Bell's Palsy
|
N/A | |
Terminated |
NCT03996525 -
Electrical Stimulation to Improve Recovery After Peripheral Nerve Injury
|
N/A | |
Enrolling by invitation |
NCT02179684 -
Surgery or Clincial Follow up, in Patients With Bell' s Palsy
|
N/A | |
Not yet recruiting |
NCT06063954 -
Two Electroacupuncture Waveforms for Different Severity Groups of Bell Palsy
|
N/A | |
Completed |
NCT04807491 -
Kabat Technique and Neuromuscular Effect in Patients With Bell's Palsy
|
N/A | |
Completed |
NCT03592797 -
Effect of Laser Acupuncture Treatment on Chronic Facial Paralysis
|
N/A | |
Recruiting |
NCT04406376 -
Do We Need to Taper Down Steroid Therapy for Bell's Palsy
|
Phase 4 | |
Recruiting |
NCT06029855 -
Kabat Rehabilitation Versus Mime Therapy on Facial Disability and Synkinesis in Patients of Bell's Palsy
|
N/A | |
Recruiting |
NCT06459830 -
Mime Therapy With and Without Neural Mobilization in Bell's Palsy.
|
N/A | |
Recruiting |
NCT06340009 -
MIME THERAPY vs MOTOR IMAGERY TECHNIQUE in Bell's Palsy
|
N/A | |
Completed |
NCT04280120 -
Effect of Neural Mobilization in Bells Palsy: A Randomized Controlled Trial
|
N/A | |
Completed |
NCT05891106 -
AONDA Therapeutic Indication Study I
|
||
Completed |
NCT03974763 -
Function and Form Outcomes in Patients With Facial Paralysis
|
||
Active, not recruiting |
NCT05997199 -
The Effect Vitamin D on the Recovery Rate of Bell Palsy
|
||
Completed |
NCT04412733 -
EFFECTÄ°VENESS OF PULSED ULTRASOUND TREATMENT ON PATIENTS WITH BELL'S PALSY
|
N/A | |
Recruiting |
NCT06028191 -
Combined Effects of Low Level Laser Therapy and Kabat Technique in Patients With Bell's Palsy
|
N/A | |
Recruiting |
NCT05582915 -
Screening for Prognostic Biomarkers of Severe Bell's Palsy in Adults
|
||
Terminated |
NCT03836989 -
Electrical Stimulation to Promote Recovery in Bells Palsy
|
N/A | |
Recruiting |
NCT05270187 -
Multiwave Locked System Laser for Patients With Bell's Palsy.
|
N/A | |
Recruiting |
NCT06308250 -
Comparative Effects of Mime Therapy and Action Observation Therapy in Bell's Palsy
|
N/A |